Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients

PHASE4RecruitingINTERVENTIONAL
Enrollment

5,000

Participants

Timeline

Start Date

January 8, 2022

Primary Completion Date

December 13, 2026

Study Completion Date

November 30, 2029

Conditions
Hepatitis B, Chronic
Interventions
DRUG

Peginterferon Alfa-2B

Different usage of peginterferon Alfa-2B and/or Nucleos(t)ide analogs in arm/group descriptions are depended on the wishes of the patient and the advice of the attending doctor.

DRUG

Nucleoside Analogs

Nucleos(t)ide analogs refer to one of the first-line drugs, including ETV, TDF and TAF.

Trial Locations (1)

510630

RECRUITING

Department of Infectious Diseases, The Third Affliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Third Affiliated Hospital, Sun Yat-Sen University

OTHER

NCT05182463 - Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients | Biotech Hunter | Biotech Hunter